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Abstract
Background: To evaluate the efficacy of Ahmed Glaucoma Valve (AGV) surgery and the optimal interval between
penetrating keratoplasty (PKP) and AGV implantation in a population of Asian patients with preexisting glaucoma who
underwent PKP.
Methodology/Principal Findings: In total, 45 eyes of 45 patients were included in this retrospective chart review. The final
intraocular pressures (IOPs), graft survival rate, and changes in visual acuity were assessed to evaluate the outcomes of AGV
implantations in eyes in which AGV implantation occurred within 1 month of post-PKP IOP elevation (Group 1) and in eyes
in which AGV implantation took place more than 1 month after the post-PKP IOP evaluation (Group 2). Factors that were
associated with graft failure were analyzed, and the overall patterns of complications were reviewed. By their final follow-up
visits, 58% of the patients had been successfully treated for glaucoma. After the operation, there were no statistically
significant differences between the groups with respect to graft survival (p=0.98), but significant differences for IOP control
(p=0.049) and the maintenance of visual acuity (VA) (p,0.05) were observed. One year after surgery, the success rates of
IOP control in Group 1 and Group 2 were 80% and 46.7%, respectively, and these rates fell to 70% and 37.3%, respectively,
by 2 years. Factors that were associated with a high risk of AGV failure were a diagnosis of preexisting angle-closure
glaucoma, a history of previous PKP, and a preoperative IOP that was .21 mm Hg. The most common surgical
complication, aside from graft failure, was hyphema.
Conclusions/Significance: Early AGV implantation results in a higher probability of AGV survival and a better VA outcome
without increasing the risk of corneal graft failure as a result of post-PKP glaucoma drainage tube implantation.
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Introduction
The presence of glaucoma following a penetrating keratoplasty
(PKP) procedure is the second most common cause of corneal
graft failure [1]. Some patients who have corneal pathology that
requires PKP have preexisting glaucoma; Reinhard et al [2]
estimated that the 3-year graft survival rate in these patients is
approximately 71%, as opposed to an 89% survival rate in patients
with no history of glaucoma. The implantation of glaucoma
drainage devices (GDDs) has therefore played an important role in
the surgical treatment of glaucoma in patients who have un-
dergone PKPs [3]. Several reports have shown that using GDDs as
a method of treating glaucoma, as is the case with Ahmed valve
(AGV) implantation, is an effective method of controlling in-
traocular pressure (IOP) in glaucoma patients. In a number of
studies, 50–80% of the patients experienced post-operative corneal
graft rejections that affected their visual acuities (VAs) [4–6]. At
present, there is no consensus regarding the amount of time
between PKP and AGV implantation that is optimal for
controlling IOP, improving graft survival, and preserving VA in
patients with preexisting glaucoma. Moreover, there have been no
studies that compare the surgical outcomes of patients who
received AGV implantations at various intervals after undergoing
PKPs.
The purpose of the present study was to evaluate the procedure
of using AGV implantation to control preexisting glaucoma
following PKP in patients from an Asian population. This study
compares the IOP, corneal graft, and visual acuity outcomes of
post-PKP patients who received AGV implantation either within 1
month of post-PKP IOP elevation or more than 1 month after
IOP elevation. The outcome measures were monitored for as long
as 2 years after PKP. In addition, the factors that were associated
with AGV failure in these patients, and the overall complications
that they experienced were also analyzed. Finally, we found that
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37867earlier AGV implantation following post-PKP IOP elevation in
patients with preexisting glaucoma and who underwent PKPs
improved the probability of tube survival and preserved VA
without increasing the likelihood of corneal graft failure.
Methods
Objectives
AGV implantation is a suitable treatment method for various
types of glaucoma, including the treatment of glaucoma that is
associated with undergoing a PKP procedure. For the most part,
the present study aimed to evaluate whether more aggressive
glaucoma treatment (early AGV implantation) was of greater
benefit to patients with preexisting glaucoma who had undergone
PKP. The study also placed a minor focus on evaluating the risk of
AGV failure in these patients.
Participants
We reviewed the medical records of patients with preexisting
glaucoma and significant corneal disease that required PKP who
were subsequently treated with AGV implantation at the De-
partment of Ophthalmology of the Tri-Service General Hospital,
Taipei, Taiwan, between January 2000 and December 2010. In
total, 73 cases were reviewed, and 28 cases were excluded because
the medical records were incomplete. A total of 45 eyes of 45
patients were included. All of the AGV implantation surgeries
were performed by the corresponding author, and no other GDDs
were used during the study period. Prospective patients who were
not able to attend follow-up visits during an extended post-
operative period were also excluded.
The patients were divided into 2 groups: Group 1 included
patients in whom AGV implantation was performed within
1 month of determining the presence of persistent IOP elevation
(measured IOP of $21 mm Hg at three successive visits), and
Group 2 included patients in whom AGV implantation was
performed more than 1 month after a persistent IOP elevation was
established. Our hospital is a tertiary referral center, so most of the
patients who were recruited for participation in our study were
referred from other hospitals. To ensure corneal graft survival, we
performed surgical interventions as soon as was possible. The
criteria that were used in grouping these patients were therefore
based on the information contained in the referral documents that
we received when the patient was referred to our hospital.
Description of Procedures
Pre- and postoperative patient demographics and clinical
characteristics, including their ages, genders, IOP measurements
(using a Goldmann applanation tonometer), corneal diagnoses,
types of preexisting glaucoma and use of antiglaucoma medica-
tions, were documented and subjected to statistical analysis.
A similar surgical technique was used to perform AGV
implantation in all patients. Under peribulbar anesthesia, we
created a fornix-based conjunctival flap in the superotemporal
quadrant between 2 adjacent recti muscles. After creating
a3 63 mm triangular scleral flap, the AGV (model S2 with
a 185 mm
2 polypropylene plate; New World Medical, Rancho
Cucamonga, CA, USA) was irrigated with balanced saline solution
(BSS; Alcon, Fort Worth, TX, USA) to prime the valve
mechanism. The polypropylene body of the implant was placed
8 mm posterior to the corneoscleral limbus and was sutured to the
sclera with an 8–0 prolene suture (Ethicon Inc., Somerville, NJ,
USA). The tube of the AGV implant was then trimmed so that the
bevel of it faced the corneal endothelial surface and was
subsequently inserted into the anterior chamber through a needle
track that had been made with a 23-gauge needle. A scleral patch
graft from a human donor was placed on the tube so that the
anterior edge was adjacent to the limbus and was then sutured to
the sclera with an 8–0 prolene suture. After the implant and graft
had been inserted, 0.5 cc of a viscoelastic solution (Healon GV
H;
Advanced Medical Optics, Santa Ana, CA, USA) was injected into
the anterior chamber to avoid early hypotony. Finally, the
conjunctiva was sutured to the limbus, and the eye received
a subconjunctival injection of steroids and antibiotics. No
adjunctive metabolites were used.
After the operation, topical eye drops containing 0.3% ofloxacin
(Tarvid, Santen, Osaka, Japan) and 1% prednisolone acetate
(EconoPred Plus, Alcon, Texas, USA) were prescribed, and their
use was tapered slowly over a period of 4–8 weeks. Antiglaucoma
medication prescriptions were adjusted on the basis of both the
IOP and the clinical status of the eye that had received the
implant. Patients were examined at a specific series of post-
operative intervals (1 day, 1 week, and 1 month after surgery) and
every 3 months thereafter for a total follow-up period of 2 years.
Slit-lamp examinations were performed, and VA, IOP, and any
surgical complications were assessed at each follow-up visit.
The outcome variable that we used to measure the success of
AGV survival was postoperative IOP control after AGV implan-
tation. Complete success was defined as having a final IOP that
was ,21 mm Hg, .6 mm Hg, and accompanied by a pressure
reduction of at least 20% relative to pre-surgery levels in the
absence of any loss of light perception, the need for any additional
antiglaucoma medication, or AGV implant removal. Partial
success was defined as a final IOP that was ,21 mm Hg,
.6 mm Hg, and accompanied by a pressure reduction of at least
20% relative to pre-surgery levels in conjunction with a need for
additional antiglaucoma medication. Patients with IOPs that were
$21 mm Hg or that were #6 mm Hg were given treatment that
attempted to lower or raise their IOPs, respectively, and they were
re-examined within several days to a week. Because these patients
required more frequent postoperative examinations than patients
in whom the AGV implant had been partially or completely
successful, the results of their additional examinations were
averaged to generate statistics for a single time frame. Neither
success nor failure was defined until at least 2 consecutive
examinations after the 3- to 6-month time frame had taken place.
Success and failure of graft clarity survival were defined as follows:
success was defined as the corneal graft remaining clear, and
failure was determined by the presence of corneal graft de-
composition. Additional outcome parameters included changes in
visual acuity, operative complications, and postoperative compli-
cations.
Ethics
The study followed the principles that were established in the
Declaration of Helsinki and was approved by the Institutional
Review Board of the hospital.
Statistical methods
The Mann-Whitney U test and Fisher’s exact test were used to
compare non-parametric continuous and categorical variables,
respectively, within the groups. Differences between the pre-
operative IOPs and the IOPs that were measured at each follow-
up examination were analyzed using Wilcoxon signed-rank tests.
Means were used to describe non-parametric data, and categorical
data were represented by numbers and percentages. Kaplan-
Meier life-table analysis was used to calculate IOP and graft
survival curves. The following factors that may have influenced the
rates of AGV failure were assessed in a logistic regression model:
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medications, lens status, total number of previous PKPs, and
postoperative IOP. All statistical assessments were two-tailed, and
a P-value of P#0.05 was considered statistically significant.
Statistical analyses were performed using version 15.0 of the SPSS
statistical software package (SPSS Inc., Chicago, IL, USA).
Results
Demographic and preoperative characteristics of Groups 1 and
2 are listed in Table 1. Data that were collected include the ages,
genders, preoperative IOPs, mean numbers of PKPs, types of
preexisting glaucoma and corneal disease diagnoses. The most
common type of glaucoma that was diagnosed in both groups was
chronic angle-closure glaucoma (55% and 60% of patients in
Groups 1 and 2, respectively). The major corneal disorder in both
groups was pseudophakic bullous keratopathy (60% and 52% in
Groups 1 and 2, respectively). The average follow-up period for
patients in Group 1 and Group 2 was 22.4 months (SD, 11.3) and
17.8 months (SD, 12.0), respectively. The average time between
PKP and AGV implantation was 74.5 days (SD, 40.5) in the
Group 1 patients and 111.4 days (SD, 43.4) in the Group 2
patients (P,0.05).
Figure 1 shows the IOP data that were obtained during the
preoperative examination and postoperative follow-up periods in
patients from Groups 1 and 2. The mean preoperative IOP of
Group 1 patients was 27.8 mm Hg (SD, 7.3), and the mean
preoperative IOP of the Group 2 patients was 29.0 mm Hg (SD,
10.9). After the operation, the mean IOPs of both groups
decreased significantly at postoperative day 1, month 1, month 3,
month 6, month 9, year 1, year 2, and year 3 (P,0.05). The
mean IOP at the final follow-up examination had also decreased
significantly in both groups; it reached a final value of 14.9 mm
Hg (SD, 4.4) in group 1 (P,0.001) and a final value of 15.0 mm
Hg (SD, 4.1) in Group 2 (P,0.001).
The rate of completely successful Ahmed valve implantation
was 40.0% (18/45), and the partial success rate of AGV
implantation was 17.8% (8/45) in all patients at the last visit.
The Kaplan-Meier life-table analysis for AGV survival in the 2
groups is shown in Figure 2. The overall cumulative probability of
success was 58.9% at 1 year after implantation and was 49.4% at
2 years after implantation. The probabilities of success in Group 1
and Group 2 were 80% and 46.7% at 1 year and 70% and 37.3%
at 2 years, respectively. There was a statistically significant
difference between the two groups with respect to final success
rate of IOP reduction (log-rank test =0.049).
The overall cumulative probabilities of corneal graft success
were 74.0% and 52.2% at 1 and 2 years postoperatively,
respectively (Figure 3). These probabilities were 73.8% and
73.6% at 1 year and 53.7% and 50.5% at 2 years in the Group
1 and Group 2 patients, respectively. There was no statistically
significant difference between the two groups with respect to final
rate of corneal graft survival (log-rank test =0.98).
Figure 4 shows a comparison of the final changes in the visual
acuities of the two groups. There was a significant difference in the
final VAs of the ‘‘worsened’’ (p=0.04, Fisher’s exact test) and
‘‘improved’’ (p=0.02) subgroups. However, there were no
differences between either of these groups and the subgroup that
experienced ‘‘no change.’’ In Group 1, 8 patients (40%) showed no
change in VA, 4 patients (20%) showed a decline in VA, and 8
patients (40%) showed an improvement in VA. Similarly, 10
patients in Group 2 (40%) had no change in VA, 8 patients (32%)
showed a decline in VA, and 7 patients (28%) showed an
improvement in VA.
The average number of antiglaucoma medications that patients
were using prior to AGV implantations was 2.3 (SD, 1.3) in
Group 1 and 1.9 (SD, 0.9) in Group 2, and the difference between
the numbers of medications taken by each group was significant
(P,0.05). After undergoing various operations, the mean number
of medications was 1.0 (SD, 1.1) in the Group 1 patients and 1.3
(SD, 1.2) in the Group 2 patients; the difference between the two
groups was not significant.
As shown in Table 2, age, gender, diagnosis, lens status, number
of previous PKPs and pre-operative IOP were analyzed as
potential risk factors for AGV implantation failure. The Cox
proportional hazards model indicated that the hazard ratio of
Table 1. Preoperative characteristics of study patients in both groups.
Group 1 Group 2 P-value
Patients (Number) 20 25 0.063
Age (Mean) 62.8 59.5 0.77
Female, No. (%) 11 (55%) 15 (60%) 0.38
Preoperative IOP (mmHg), mean (SD) 30.3 (5.28) 27 (6.25) 0.057
Duration between PK and persistent IOP elevation (days), mean (SD) 56.3 (39.9) 58.0 (42.3) 0.93
Preoperative antiglaucoma medications, mean (SD) 2.3 (1.3) 1.9 (0.9) 0.03
a
Type of preexisting glaucoma diagnosis, No. (%) 0.43
Primary open angle 4 (20) 5 (20)
Chronic angle closure 11 (55) 15 (60)
Secondary (trauma, uveitis) 3 (15) 4 (16)
Other 3 (15) 1 (4)
Type of corneal diagnosis, No. (%) 0.58
Pseudophakic bullous keratopathy 12 (60) 13 (52)
Failed PK 5 (25) 7 (28)
Other 3 (15) 5 (20)
Abbreviations: IOP = intraocular pressure; SD = standard deviation;
aDenotes statistical significance.
doi:10.1371/journal.pone.0037867.t001
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a diagnosis of preexisting glaucoma, the number of previous
PKPs, and the pre-operative IOP after the AGV. The chronic
angle-closure glaucoma patients appeared to be predisposed to
higher rates of failure compared with other patients (OR, 3.55;
95% CI, 1.05–5.79; P=0.034). In addition, having two or three
previous PKPs was associated with an elevated risk of failure (ORs,
1.63 and 1.92, respectively; 95% CIs, 1.39–1.93 and 1.78–2.28,
respectively; P=0.042) as was an individual’s preoperative IOP
(OR, 3.01; 95% CI; 2.50–5.20; P=0.02).
The postoperative complications that occurred in patients in
both groups are summarized in Table 3. The most frequent
complications (in order of decreasing frequency) were as follows:
corneal graft failure or rejection, hyphema, and the presence
shallow anterior chamber.
Discussion
Ahmed glaucoma valve implantation often enables the success-
ful control of refractory glaucoma in cases in which other surgical
modalities are ineffective [7–12]. This undoubtedly poses a chal-
lenge to the surgical management of patients with preexisting
glaucoma who have undergone PKPs. It has also been shown that
pre-existing glaucoma is a risk factor for graft failure [13].
Although various types of GDDs have been effective in IOP
control, many patients who received GDD implants have shown
poor corneal graft outcomes with graft failure rates that ranged
from 10 to 51% [3,14–18]. Several studies have investigated the
effect of the relative sequence of PK and GDD on graft survival.
Rapuano et al [19] found evidence of a tendency toward
decreased graft survival when a GDD was implanted after a patient
had undergone PK. However, Coleman et al [6] found that there
was no difference in outcomes when an AGV was implanted
concurrently with or after a PK. Kwon et al [10] reported that
eyes in which a GDD had been implanted prior to PK have
a higher risk for graft failure than eyes in which GDDs were
implanted concurrently with or after PKs. They also considered
the fact that these patients tend to have severe glaucoma, which in
turn could affect graft survival. In the case series that we reviewed
in the present study, the total corneal graft survival rate was 52.2%
at 2 years postoperatively, which is similar to the survival rate that
Figure 1. Pre- and postoperative intraocular pressures following Ahmed glaucoma valve implantation surgery in Group 1 and
Group 2 over time. A marked decrease in the median IOP relative to the baseline IOP was noted during each postoperative period.
doi:10.1371/journal.pone.0037867.g001
Figure 2. Kaplan-Meier life-table analysis showing the cumu-
lative probabilities of IOP control at 1 year and 2 years post-
PKP in Group 1, Group 2, and the entire sample population
following Ahmed glaucoma valve implantation either with or
without the use of antiglaucoma medications. (Log-Rank test
=0.049).
doi:10.1371/journal.pone.0037867.g002
Figure 3. Kaplan-Meier life-table analysis showing the cumu-
lative probabilities of graft survival at 1 year and 2 years post-
PKP in Group 1, Group 2, and the entire sample population
following Ahmed glaucoma valve implantation either with or
without the use of antiglaucoma medications. (Log-Rank test
=0.98).
doi:10.1371/journal.pone.0037867.g003
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statistically significant difference in the graft survival rates of the
two groups. However, the success rate for controlling glaucoma
was significantly higher among Group 1 patients compared with
the success rate among Group 2 patients. These results demon-
strate that early surgery can effectively improve the success rate in
controlling glaucoma without inducing an increased risk of graft
failure. In addition, several other mechanisms have been
associated with a potentially higher risk of graft failure, such as
excessive surgical time, multiple procedures, excessive postopera-
tive inflammation, or early tube endothelial touch [10,14].
Fortunately, these factors did not play especially strong roles in
the clinical histories and outcomes of our patients. We performed
anterior chamber injections of 0.5 cc of a viscoelastic solution
(Healon GV
H; Advanced Medical Optics, Santa Ana, CA, USA)
and used AGV tubes of relatively short lengths to avoid
complications such as early shallow anterior chamber and early
tube endothelial touch after the suture in our patients.
Goldberg’s study found that 71% of patients with pre-existing
glaucoma developed increased IOPs early in the postoperative
course following PKP [20]. In the present case series, AGV
implantation succeeded in controlling glaucoma in 80% and 71%
of patients at 1 and 2 years, respectively. Alvarenga et al [14]
reported that eyes in which Ahmed valves were implanted had
glaucoma control success rates of 74% and 63.1% at 1 and
2 years, respectively, which are higher than the success rates in our
patients. This finding may be a result of the time at which the
AGV was implanted. In our study, an aggressive therapeutic
protocol in which an AGV was implanted within 1 month of the
establishment of elevated IOP (Group 1) showed survival rates of
AGV implantation that were similar to those of previous reports,
whereas a less intensive treatment protocol in which AGV
implantation occurred more than 1 month after an elevated IOP
was established (Group 2) yielded an opposite result. Furthermore,
the inclusion of eyes with different types of preexisting glaucoma
may play a role in this issue. Our study differs from other studies
that have been mentioned in that the majority of patients who
were included in it had chronic angle-closure glaucoma. In
general, AGV implantation has been thought to be relatively
effective with respect to controlling glaucoma in different types of
patients [21,22], and neither glaucoma nor corneal diagnosis has
been shown to influence the success of long-term glaucoma control
with GDDs. However, our experience has shown the success rate
of AGV implantation may be influenced by the type of glaucoma;
for example, we have found evidence of poor outcomes of AGV
implantation in controlling neovascular glaucoma [22]. Further-
more, our Cox regression analysis also showed that the patients
with preexisting angle-closure glaucoma had an increased risk of
AGV failure compared with other patients. Thus, we believe that
the clinical characteristics of patients with different types of
glaucoma may differ and could result in diverse outcomes.
Escalation of glaucoma therapy often immediately follows PKP
in patients with a preexisting glaucoma condition [23] in which the
rapid onset of IOP control could diminish the severity of optic
nerve damage. In our study, a short latency between PKP and
AGV implantation is related to the improved success rate of AGV
implantation and to the preservation of VA. An increased duration
of elevated IOP prior to Ahmed valve implantation may lead to
greater inflammation that could cause further damage to the
trabecular cells [24]. Therefore, earlier AGV implantation may
Figure 4. Visual acuity status at the final follow-up visit in
Groups 1 and 2.
doi:10.1371/journal.pone.0037867.g004
Table 2. Logistic regression analysis of risk factors for AGV
failure at 2 years.
Hazard
Ratio 95% CI P-value
Age (years) 0.054
,60 1.00 –
§60 1.03 (1.00, 1.05)
Gender 0.494
Male 1.00 –
Female 1.08 (0.55, 3.44)
Diagnosis (glaucoma type) 0.034
a
Primary open angle 1.00 –
Chronic angle closure 3.55 (1.05, 5.79)
Secondary (trauma, uveitis) 2.44 (0.84, 4.41)
Lens status 0.064
Pseudophakia 1.00 –
Aphakia 1.17 (0.77, 5.16)
Phakia 1.08 (0.73, 4.98)
Previous PKs 0.041
a
One 1.00 –
Two 1.63 (1.39, 1.93)
Three 1.92 (1.78, 2.28)
Postoperative IOP 0.02
a
,21 1.00 –
§21 3.01 (2.5, 5.2)
Abbreviations: CI = confidence interval; IOP = intraocular pressure; PK =
penetrating keratoplasty;
aDenotes statistical significance.
doi:10.1371/journal.pone.0037867.t002
Table 3. Postoperative complications in the 2 study groups.
Group 1 (No., %) Group 2 (No., %)
Shallow anterior chamber 2, 10 3, 12
Corneal graft failure or rejection 8, 40 8, 32
Serous choroidal detachment 1, 5 0, 0
Encapsulated bleb 1, 5 1, 4
Tube malposition 1, 5 1, 4
Diplopia 0, 0 1, 4
Hypotony 2, 10 2, 8
Fibrinous iridocyclitis 0, 0 1, 4
Hyphema 3, 15 3, 12
doi:10.1371/journal.pone.0037867.t003
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lessening the degree of trabecular cell death. In addition, we also
found that patients who underwent AGV implantation shortly
after PKP generally had better VA outcomes than patients for
whom the interval between PKP and AGV implantation was
longer. Although the visual field data to support this result were
not available, we speculate that this result might be due to the
lessening of optic damage that resulted from early IOP control.
The Cox regression analysis that we conducted showed that the
type of glaucoma with which a patient had been diagnosed, the
number of previous PKPs, and the duration of IOP elevation prior
to AGV implantation were all associated with an increased risk of
AGV failure. The majority of our patients had chronic angle-
closure glaucoma, which was associated with a higher risk of AGV
failure. No previous study has found evidence of an increased rate
of AGV failure in angle-closure glaucoma. We suggest that this
increase may result from having a narrow angle space that is
occupied by a tube. The presence of the tube may easily cause
anterior chamber inflammation due to friction against the angle
walls. Moreover, inflammation in the anterior chamber may
decrease the AGV success rate, which is the case in uveitic
glaucoma [25]. Multiple previous PKPs can lead to an increased
tendency to develop anterior chamber synechiae and corneal
neovascularization [26], which may also result in a high risk of
AGV failure. Preoperative IOP elevation may reflect a refractory
disease status in which the disease cannot readily be controlled by
drugs or by laser therapy. Thus, the elevated risk of AGV failure
that has been observed in these patients was reasonable.
In our study, the most common early postoperative complica-
tion was hyphema, followed by a shallow anterior chamber. The
incidence of hyphema following AGV implantation has been
reported to occur in approximately 2%–20% of patients, and it
typically resolves without surgical intervention [17,21,27,28]. The
incidence of a shallow anterior chamber following the implanta-
tion of an Ahmed valve has been reported to be 0–15%
[17,21,27,28]. Differences between these reports and our findings
might be explained by the clinical statuses of our patients and by
the particular variation in the surgical technique that we used in
which a viscoelastic solution was injected immediately following
valve implantation to prevent early hypotony or choroidal
effusions. Fortunately, this condition typically resolves spontane-
ously without additional surgery. No serious complications that
involved VA losses or blindness occurred among our patients.
There are several limitations to our study. The retrospective
design with variable follow-up intervals may result in certain
patient selection biases, and the inclusion of patients with various
glaucoma diagnoses resulted in a relatively small sample size.
However, it is difficult to conduct a prospective and randomized
trial because of ethical concerns and because the amount of time
that elapses between PKP and AGV implantation cannot be
masked. Moreover, the continual availability of new drugs makes it
impossible to control for type of ocular medications. The VAs of
some patients might be influenced by both corneal pathology and
preexisting glaucoma, which in turn may also result in certain
biases in the assessment of VA. Antiglaucoma drug use was more
prominent among patients in group 1, which may reflect
a generally greater severity of glaucoma in this group. The
elevated severity of glaucoma may have proceeded to interfere
with the success rate of AGV implantation. Another possible
reason for some of the observed inter-group differences is that the
patients in group 1 were referred by an aggressive corneal
specialist who may have attempted to use an intensive protocol for
controlling IOP that involved the use of multiple antiglaucoma
drugs. In contrast, better IOP control should be more easily
achieved in patients with less severe diagnoses, and our results
showed that IOP control was more successful in the group with
more severe glaucoma. In other words, patients who were
categorized as belonging to Group 1 were primarily treated
during the latter half of the 10-year study period, which means
that a change in surgical practice and decision making may have
occurred. A change in surgical practice would suggest that the
observed improvement in the IOPs of Group 1 patients was
actually due to earlier intervention more than to the possibility of
a patient selection bias.
In conclusion, AGV implantation appears to be a viable option
for controlling IOP in patients with preexisting glaucoma after
penetrating keratoplasty (PKP). In addition, we found that early
AGV implantation results in a higher rate of AGV implant
survival and a better VA outcome compared with delayed AGV
implantation without increasing the risk of graft failure. There is
also a low incidence of severe postoperative complications with the
notable exception of graft decomposition. However, graft failure
remains a challenge in such patients.
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